Discover Astex
Our Mission & Values
Our Leadership Team
Our History
Corporate Social Responsibility
R&D
Clinical Pipeline
Proprietary Products and Programs
Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
Partnered Products and Programs
Kisqali
®
(ribociclib) CDK4/6 inhibitor (Oncology)
Balversa
®
(erdafitinib) FGFr inhibitor (Oncology)
Truqap™ PKB/Akt Inhibitor (Oncology)
Multiple Targets and Therapeutic Areas
Pyramid™ Discovery Platform
Oncology and CNS Discovery
Sustaining Innovation Postdocs
Partnering
Our People & Culture
Career Opportunities
Media
Press Releases
Conferences & Meetings
Presentations & Publications
Interactive Scientific Resources
Interactive Software
Astex in the News
Contact
Search
Menu
Menu
You are here:
Home
1
/
Sitemap
Site Map
Discover Astex
Our Mission & Values
Our Leadership Team
Our History
Corporate Social Responsibility
R&D
Clinical Pipeline
Proprietary Products and Programs
Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
Partnered Products and Programs
Kisqali
®
(ribociclib) CDK4/6 inhibitor (Oncology)
Balversa
®
(erdafitinib) FGFr inhibitor (Oncology)
Truqap™ PKB/Akt Inhibitor (Oncology)
Multiple Targets and Therapeutic Areas
Pyramid™ Discovery Platform
Oncology and CNS Discovery
Sustaining Innovation Postdocs
Partnering
Our People & Culture
Career Opportunities
Media
Press Releases
Conferences & Meetings
Presentations & Publications
Interactive Scientific Resources
Interactive Software
Astex in the News
Contact
Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
